According to literature reports, EA had inhibition effects on multiple targets of cancer cells, such as VEGFR-2 [14], STAT3 [28], TGF-β [29], and NF-κB [30], etc. However, this is the first study to demonstrate the direct target of EA in cancer cells, and a more comprehensive strategy, such as network pharmacology, might be used to establish the anti-cancer network signaling of EA in the future. This evidence concerns the gene TGFB1 and cancer.